Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > ACADEMIA
ACADEMIA
- JSNP Finalizes Evidence-Based Guidelines for Treatment of Schizophrenia
September 28, 2015
- Experts, Industry Execs Say Cost Calculation Drug Pricing Method Fraught with Challenges
September 8, 2015
- ASCO Immunotherapy Roundup - 9: Researcher Says Predominance of Anti-PD-1 Antibodies Not Assured
September 1, 2015
- Japan’s National Database “World’s Largest in Scale”: Kyoto University Prof. Nakayama
August 20, 2015
- Genome Sequencing Study of Biliary Tract Cancer Suggests Effectiveness of Immune Checkpoint Therapy: National Cancer Center
August 12, 2015
- St. Marianna Univ. Hospital Introduces Tougher Rules for Adopting New Drugs with Emphasis on Cost, Efficacy, and Safety
July 28, 2015
- PD-L1 Expression Key to Decide Whether to Combine Opdivo, Yervoy: Oncologist
July 21, 2015
- Japan, US Oncologists Exchange Barbs over Opdivo Costs
July 21, 2015
- Japan Lung Cancer Society Petitions Health Minister for Early Approval of AZ’s AZD9291 for EGFR-TKI-Resistant NSCLC
July 8, 2015
- NCC Starts PI Study of Nucleic Acid Drug in Treatment-Resistant Locally Advanced or Recurrent Breast Cancer
July 8, 2015
- JSGM to Issue Policy Proposal after MHLW Sets New Target for Generic Market Share
June 17, 2015
- AGs “Will Energize the Generic Drug Market”: Prof. Sakamaki
June 17, 2015
- MHLW Official Urges Generic Drug Makers to Expand into Overseas Markets
June 17, 2015
- MHLW Official Restates Difficulty of Moving Up Timeline to Attain 80% Generic Share
June 16, 2015
- Tiotropium Positioned in Step 3 and Step 4 Care for Asthma: Japanese Society of Allergology’s Revised Guidelines
June 5, 2015
- Pfizer Poised to Emerge as Global Leader in Oncology: Chief Medical Officer
June 3, 2015
- Xtandi Monotherapy Meets Primary Endpoint in PII Study for Triple-Negative Breast Cancer: Astellas
June 3, 2015
- 3 of 20 Japanese Gastric Cancer Patients Show PR to PD-L1 Inhibitor Avelumab: ASCO
June 3, 2015
- Ibrance Prolongs PFS in Second-Line for Advanced Breast Cancer: ASCO
June 3, 2015
- BBI608, BBI503 Exert Antitumor Activity in Multiple Studies: Sumitomo Dainippon
June 3, 2015
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…